Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG4B | Q9Y4P1 | 4/20 | 0.55 |
| ▸ | KMO | O15229 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783467 | 0.93 | MEN1 (0.58) | ATG4BKMOMEN1KMT2ARAB9A | |
| SCHEMBL7978716 | 0.84 | STAT3 (0.59) | ATG4BKMOMEN1KMT2ARAB9A | |
| SCHEMBL10526102 | 0.80 | MEN1 (0.56) | ATG4BMEN1KMT2ARAB9AMAPT | |
| SCHEMBL4892513 | 0.79 | AKT1 (0.47) | ATG4BKMOMEN1KMT2ARAB9A | |
| SCHEMBL28579597 | 0.77 | MEN1 (0.63) | ATG4BMEN1KMT2ARAB9AMAPT | |
| SCHEMBL8694330 | 0.76 | MEN1 (0.60) | ATG4BMEN1KMT2ARAB9AMAPT | |
| SCHEMBL3251168 | 0.75 | MAPT (0.51) | KMOMEN1KMT2ARAB9AMAPT | |
| SCHEMBL3252170 | 0.74 | MMP1 (0.48) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL29057037 | 0.74 | STAT3 (0.53) | ATG4BMEN1KMT2ARAB9AMAPT | |
| SCHEMBL1804664 | 0.73 | MEN1 (0.68) | ATG4BMEN1KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001090093-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | claimed |
| US-20080033046-A1 | Treatment of myocardial infarction with 11HSD1 inhibitors | UNIVERSITY OF EDINBURGH (GB) | 2008-02-07 | — | — | US | disclosed |
| WO-2001090093-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033046-A1 | Treatment of myocardial infarction with 11HSD1 inhibitors | HSD11B1, HSD11B2, CYP11B1 | ATG4B 1689/4885KMO 947/4885MEN1 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.